Zacks Research Comments on Dr. Reddy’s Laboratories Limited’s Q1 2026 Earnings (NYSE:RDY)

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Equities research analysts at Zacks Research lowered their Q1 2026 EPS estimates for shares of Dr. Reddy’s Laboratories in a report issued on Wednesday, May 1st. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.01 for the quarter, down from their prior forecast of $1.02. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $3.96 per share.

RDY has been the topic of a number of other research reports. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Barclays lifted their price objective on shares of Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the company an “overweight” rating in a research report on Monday, January 29th. Finally, Jefferies Financial Group downgraded Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research report on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $80.00.

Dr. Reddy’s Laboratories Stock Performance

Shares of Dr. Reddy’s Laboratories stock traded up $0.39 on Friday, reaching $75.17. The stock had a trading volume of 99,886 shares, compared to its average volume of 193,960. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.90 and a current ratio of 2.55. The business’s 50-day moving average price is $74.02 and its two-hundred day moving average price is $70.64. Dr. Reddy’s Laboratories has a fifty-two week low of $53.12 and a fifty-two week high of $77.72. The stock has a market cap of $12.54 billion, a P/E ratio of 19.73, a price-to-earnings-growth ratio of 1.85 and a beta of 0.57.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.99 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.11. Dr. Reddy’s Laboratories had a net margin of 19.26% and a return on equity of 20.97%. The company had revenue of $867.00 million for the quarter, compared to the consensus estimate of $827.81 million.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its stake in Dr. Reddy’s Laboratories by 8.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 115,499 shares of the company’s stock valued at $8,036,000 after purchasing an additional 9,414 shares during the last quarter. Sequoia Financial Advisors LLC boosted its position in Dr. Reddy’s Laboratories by 3.6% in the 4th quarter. Sequoia Financial Advisors LLC now owns 14,294 shares of the company’s stock valued at $995,000 after buying an additional 501 shares during the period. Wellington Management Group LLP increased its holdings in Dr. Reddy’s Laboratories by 40.7% during the 3rd quarter. Wellington Management Group LLP now owns 141,154 shares of the company’s stock worth $9,439,000 after purchasing an additional 40,825 shares during the period. Nordea Investment Management AB raised its holdings in Dr. Reddy’s Laboratories by 5.3% in the third quarter. Nordea Investment Management AB now owns 23,855 shares of the company’s stock valued at $1,601,000 after acquiring an additional 1,196 shares in the last quarter. Finally, Schroder Investment Management Group lifted its position in shares of Dr. Reddy’s Laboratories by 62.4% during the 3rd quarter. Schroder Investment Management Group now owns 150,165 shares of the company’s stock worth $10,042,000 after purchasing an additional 57,681 shares during the last quarter. Hedge funds and other institutional investors own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.